U.S. CDMRP – Lung Cancer Research Program | Research Funding

Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2024 Lung Cancer Research Program (LCRP) Awards. Several award programs are available:

• The Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. Research applications only in the area of mesothelioma will not be accepted. This award is intended to support impactful research projects with an emphasis on discovery.
   
• The intent Concept Award is to support innovative, non-incremental, high risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications in lung cancer. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. Research applications only in the area of mesothelioma will not be accepted.
   
• The Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Research applications only in the area of mesothelioma will not be accepted. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.
   
• The Patient-Centered Outcomes and Survivorship Award supports high-risk, high-reward research studies that span the spectrum of behavioral health science, survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions, and examining the physical, psychological, social, and economic effects of lung cancer among patients and their families.
   
• The Translational Research Award mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application.

• Career Development Award: max. $375,000
• Concept Award: max. $120,000
• Idea Development Award: max. $525,000
• Patient-Centered Outcomes and Survivorship Award: max. $650,000
• Translational Research Award: $900K – 1.2M

• Career Development Award: 3 years
• Concept Award: 1 year
• Idea Development Award: 3 years
• Patient-Centered Outcomes and Survivorship Award: 3 years
• Translational Research Award: 3-4 years

• 28 May 2024, 5:00 p.m. Eastern time
  • Career Development Award
  • Concept Award
  • Idea Development Award
  • Translational Research Award
• 17 July 2024, 5:00 p.m. Eastern time
  • Patient-Centered Outcomes and Survivorship Award

• 17 June 2024, 11:59 p.m Eastern Time
  • Career Development Award
  • Concept Award
• 07 August 2024, 11:59 p.m Eastern Time
  • Idea Development Award
  • Translational Research Award
  • Patient-Centered Outcomes and Survivorship Award

• To find the full program announcements and to start your pre-application see here
• A useful summary of each call can be found here
• For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
• Grants.gov Funding Opportunity Numbers:
  • Career Development Award: HT942524LCRPCDA
  • Concept Award: HT942524LCRPCA
  • Idea Development Award: HT942524LCRPIDA
  • Patient-Centered Outcomes and Survivorship Award: HT942524LCRPPCOSA
  • Translational Research Award: HT942524LCRPTRA

• Biology and Etiology
  • Understand the molecular mechanisms of initiation and progression to lung cancer.
  • Understand contributors to lung cancer development other than tobacco.
  • Understand the biology of metastatic/oligometastatic disease progression
• Prevention
  • Identify innovative strategies for prevention of the occurrence of lung cancer(s) or subsequent primaries.
  • Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
• Detection, Diagnosis, and Surveillance
  • Improve and expand approaches to screening and early detection of lung cancer.
  • Identify strategies for prompt detection and/or characterization of progressive disease.
• Treatment and Prognosis
  • Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
  • Develop or optimize biomarkers to assist with therapeutic decision-making.
  • Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.
• Health Outcomes and Survivorship
  • Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on patients, families, and support systems with respect to the impact on quality of life including, but not limited to, physiological, psychosocial, cognitive, and financial effects.
  • Identify and understand impact of comorbidities on survivorship care in all stages of lung cancer.
• Disparities
  • Advance equity and reduce lung cancer disparities among underserved and underrepresented populations.